Myosin II plays the most important role in cellular force generation. Myosin II molecules self-assemble into filaments with different structures depending on myosin II isoforms and other conditions ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Every cell in the body normally has its fixed place as part of a tissue structure. Except for a few cell types, such as blood ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

Returning to TikTok this week felt a bit like remote working through a natural disaster: Business as usual, except not really ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset aficamten. Read more here.

Spire Wealth Management bought a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) in the fourth quarter, ...